Tags

Type your tag names separated by a space and hit enter

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.
Emerg Infect Dis. 2005 Mar; 11(3):411-6.EI

Abstract

The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines.

Authors+Show Affiliations

Wohl Virion Centre and Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, London, UK. nigel.temperton@ucl.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15757556

Citation

Temperton, Nigel J., et al. "Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus With Pseudotypes." Emerging Infectious Diseases, vol. 11, no. 3, 2005, pp. 411-6.
Temperton NJ, Chan PK, Simmons G, et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis. 2005;11(3):411-6.
Temperton, N. J., Chan, P. K., Simmons, G., Zambon, M. C., Tedder, R. S., Takeuchi, Y., & Weiss, R. A. (2005). Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerging Infectious Diseases, 11(3), 411-6.
Temperton NJ, et al. Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus With Pseudotypes. Emerg Infect Dis. 2005;11(3):411-6. PubMed PMID: 15757556.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. AU - Temperton,Nigel J, AU - Chan,Paul K, AU - Simmons,Graham, AU - Zambon,Maria C, AU - Tedder,Richard S, AU - Takeuchi,Yasuhiro, AU - Weiss,Robin A, PY - 2005/3/11/pubmed PY - 2005/4/29/medline PY - 2005/3/11/entrez SP - 411 EP - 6 JF - Emerging infectious diseases JO - Emerg Infect Dis VL - 11 IS - 3 N2 - The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines. SN - 1080-6040 UR - https://www.unboundmedicine.com/medline/citation/15757556/Longitudinally_profiling_neutralizing_antibody_response_to_SARS_coronavirus_with_pseudotypes_ L2 - https://www.cdc.gov/ncidod/EID/vol11no03/04-0906.htm DB - PRIME DP - Unbound Medicine ER -